Richter Eyeing 20%+ Margin On Denosumab As Part Of 2027 Profit Plans

Gedeon Richter is feeling good about its plan to launch a biosimilar denosumab product in the EU in 2025, as it continued to slow down losses for its biopharma unit ahead of plans to swing to profitability later in the decade.